Evrys Bio LLC
Biotechnology company developing host-directed, broad‑spectrum small‑molecule antivirals that modulate human sirtuin enzymes (especially SIRT2) to enhance intrinsic cellular antiviral defenses. Activities focus on preclinical discovery, in‑vitro and in‑vivo efficacy testing across multiple virus families, intellectual property licensing, and government‑funded program development for clinical translation and biodefense applications.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Products
Pipeline: Pan‑respiratory antiviral program
Preclinical program developing small‑molecule host‑directed antivirals intended to act against coronaviruses, respiratory syncytial virus, adenoviruses and influenza strains.
Pipeline: Antivirals for immunosuppressed/transplant patients
Preclinical program aimed at a single‑pill approach to protect immunosuppressed patients from multiple opportunistic infections (herpes family viruses, polyomaviruses).
Pipeline: Biodefense medical countermeasure program
Program to develop scalable, broad‑spectrum medical countermeasures for newly emerging or engineered viral threats.
Pipeline: Broad‑spectrum hepatitis antiviral
Program targeting the major causes of viral hepatitis (including hepatitis B, C, D and E) via host‑directed modulation of sirtuin biology.
Pipeline: Pan‑respiratory antiviral program
Preclinical program developing small‑molecule host‑directed antivirals intended to act against coronaviruses, respiratory syncytial virus, adenoviruses and influenza strains.
Pipeline: Antivirals for immunosuppressed/transplant patients
Preclinical program aimed at a single‑pill approach to protect immunosuppressed patients from multiple opportunistic infections (herpes family viruses, polyomaviruses).
Pipeline: Biodefense medical countermeasure program
Program to develop scalable, broad‑spectrum medical countermeasures for newly emerging or engineered viral threats.
Pipeline: Broad‑spectrum hepatitis antiviral
Program targeting the major causes of viral hepatitis (including hepatitis B, C, D and E) via host‑directed modulation of sirtuin biology.
Services
Discovery, optimization and preclinical testing of host‑directed small‑molecule antivirals.
Licensing of university inventions and management of patent assets related to sirtuin‑targeted antivirals.
Discovery, optimization and preclinical testing of host‑directed small‑molecule antivirals.
Licensing of university inventions and management of patent assets related to sirtuin‑targeted antivirals.
Expertise Areas
- Host‑directed antiviral drug discovery
- Preclinical virology and infectious disease models
- Small‑molecule medicinal chemistry
- Epigenetic modulation of viral genomes
Key Technologies
- Sirtuin (SIRT2) modulation by small molecules
- Host‑directed antiviral therapeutic approach
- In‑vitro antiviral assays
- Animal infection models
News & Updates
Company poster and science update presented at BioCentury Chicago conference.
Patent allowing claims directed to antiviral treatments using inhibitors of two or more sirtuins (exclusive license from a university).
Awarded a DOD STTR contract to advance host‑targeted antiviral medical countermeasures against Marburg virus.
Multiple NIH SBIR awards including a FastTrack Phase II notice supporting sirtuin agonists as pan‑influenza antivirals.
Final close of Series A‑1 financing to fund progression of host‑targeted antiviral programs.
Preclinical report describing inhibition of hepatitis B virus covalently closed circular DNA establishment and transcription via SIRT2 modulation.
Company poster and science update presented at BioCentury Chicago conference.
Patent allowing claims directed to antiviral treatments using inhibitors of two or more sirtuins (exclusive license from a university).
Awarded a DOD STTR contract to advance host‑targeted antiviral medical countermeasures against Marburg virus.
Multiple NIH SBIR awards including a FastTrack Phase II notice supporting sirtuin agonists as pan‑influenza antivirals.
Final close of Series A‑1 financing to fund progression of host‑targeted antiviral programs.
Preclinical report describing inhibition of hepatitis B virus covalently closed circular DNA establishment and transcription via SIRT2 modulation.